ro7247669
mAbexperimentalMulti-specific
Clinical trial activity
9 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
8
Phase 3
0
Phase 4
0
Earliest trial started Nov 8, 2019 (NCT04140500)
Timeline
Indications
Studied for
Mechanism of action
- Programmed cell death protein 1INHIBITOR
PDCD1 inhibitor
- Lymphocyte activation gene 3 proteinINHIBITOR
LAG3 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5315001 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05908786 | Phase 1/Phase 2 (Phase 2) | Dec 5, 2023 | Roche |
| NCT05852691 | Phase 2 | Jul 18, 2023 | Roche |
| NCT05805501 | Phase 2 | Apr 21, 2023 | Roche |
| NCT05775289 | Phase 2 | Mar 15, 2023 | Roche |
| NCT05645692 | Phase 2 | Jan 16, 2023 | Roche |
| NCT05419388 | Phase 2 | Aug 15, 2022 | Roche |
| NCT05116202 | Phase 1/Phase 2 (Phase 2) | Nov 29, 2021 | Roche |
| NCT04785820 | Phase 2 | Jun 25, 2021 | Roche |
| NCT04140500 | Phase 1 | Nov 8, 2019 | Roche |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 9 | 9 | 2 | 2019 |
1 organizations
Page 1 / 1